15 independently sourced, verified trend briefs about this subject.
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 2 news categories, from Jun 26, 2026 through Jul 30, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
Use of GLP-1 weight loss medications has reached a new high in the United States, sparking debate over long-term efficacy and accessibility.
GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.
Medicare now provides access to GLP-1 weight-loss drugs as utilization rates among U.S. adults reach one in eight.
AstraZeneca shares rise after Q2 2026 earnings beat driven by strong cancer drug sales.
The FDA has approved the first oral medication designed to replace injectable treatments for high cholesterol.
FDA advisory committees have issued split decisions on the legal path for peptides amid high-profile advocacy for their wider availability.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company used deceptive and false advertising regarding GLP-1 weight-loss medications.
Bristol Myers Squibb is partnering with Nvidia to build what it describes as the most powerful AI supercomputer in the life sciences industry.
The FDA has approved Lipfendra, the first-of-its-kind oral PCSK9 inhibitor designed to significantly reduce cholesterol levels.
Emerging Alzheimer’s drug candidates are generating global attention as researchers and health advocates evaluate their potential to stop the disease.
Researchers and investors are evaluating new clinical data from Biogen as the firm explores tau-targeting treatments for Alzheimer’s disease.
The Wegovy weight loss pill has launched in the UK, marking the arrival of the first daily oral GLP-1 medication for weight management.
Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.
A US House committee has launched an investigation into drug trials conducted in China by major pharmaceutical companies, including Merck and AbbVie.
European regulators are recommending the revocation of marketing authorization for Amgen's rare-disease drug Tavneos following new data.